# Clinical Trials Data EGFR - Document 12

# Biomarkers in Blood Samples From Patients With Refractory Non-Small Cell Lung Cancer Previously Treated With Sorafenib Tosylate

## Clinical Trial: https://clinicaltrials.gov/study/NCT01124669

"eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n\* Diagnosis of refractory non-small cell lung cancer\n\* Received sorafenib tosylate on protocol ECOG-E2501\n\* Available blood specimens\n\nPATIENT CHARACTERISTICS:\n\n\* Not specified\n\nPRIOR CONCURRENT THERAPY:\n\n\* See Disease Characteristics",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
],  
 "studyPopulation": "Samples submitted for research from patients enrolled on E2501",

Question:  
Based on the following clinical trial information, would a patient with a EGFR gene mutation be eligible for the clinical trial?

Answer:  
This trial information \*\*does not mention EGFR mutation status\*\* as either an inclusion or exclusion criterion. Therefore, we \*\*cannot determine\*\* if a patient with an EGFR mutation would be eligible based on this text alone.   
  
The criteria focus on prior treatment with sorafenib tosylate on a specific protocol (ECOG-E2501) and having refractory non-small cell lung cancer. EGFR mutation status is a key factor in determining treatment options for lung cancer, so it's likely relevant, but it's simply not addressed in this excerpt.